DARE logo

DARE BIOSCIENCE INC

DARENASDAQ
πŸ† #4835 by market capUS Equity
$0.42β–Ό $0.02 (βˆ’4.91%)
Market closed Β· at close
πŸ””
Track DARE
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.9%
7dβ–Ό 35.4%
14dβ–Ό 32.8%
30dβ–Ό 36.5%
ytdβ–Ό 78.4%
1yβ–Ό 74.9%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
10429.4%
High Growth
πŸ“ŠGross Margin
-12.9%
Thin
πŸ’΅FCF Margin
-1288.8%
Thin
βš–οΈP/S Ratio
5.7x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.42 – $0.44
52-Week Range
$0.41 – $3.78
Volume (shares)
2,755
Avg Volume (shares)
β€”
Shares Outstanding
19.7M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$187,546
P/E Ratio
-0.6
P/S Ratio
5.7x
EPS (TTM)
$-0.61
Dividend Yield
0.00%
DARE logo

DARE BIOSCIENCE INC

DARE
Financial Trends

Financial history unavailable.

StockOtter Β· stockotter.space

About DARE BIOSCIENCE INC

DarΓ© Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. DarΓ© Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.